Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer

30. oktober 2026 opdateret af: Kamran Salari, Emory University

A Randomized Pragmatic Study of CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer

This clinical trial studies the safety of a computed tomography (CT) scan, with or without a magnetic resonance imaging (MRI) scan, in planning for high-dose-rate (HDR) prostate brachytherapy treatment in patients with prostate cancer. Brachytherapy is a type of radiation therapy in which radioactive implants, such as pellets, seeds, ribbons, wires, needles, balloons, or capsules, are placed in the body, directly into or near the tumor. The radiation is delivered through a flexible tube called a catheter or a larger device called an applicator. Treatment planning, or simulation, is a process used to plan radiation therapy so that the target area is precisely located and marked. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. An MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. The addition of MRI to CT for HDR prostate brachytherapy treatment planning may help patients have less urine leakage and less pain after treatment.

Studieoversigt

Detaljeret beskrivelse

PRIMARY OBJECTIVE:

I. To compare acute changes in patient reported outcomes of urinary toxicity utilizing the Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.

SECONDARY OBJECTIVES:

I. To compare acute and chronic changes in patient reported outcomes of toxicity utilizing the EPIC-26 Urinary Irritative/Obstructive, Bowel, and Sexual domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.

II. To compare the cumulative incidence of physician reported Common Terminology Criteria for Adverse Events (CTCAE) acute and chronic grade 2+ genitourinary (GU) or gastrointestinal (GI) toxicity for patients undergoing prostate HDR brachytherapy planned with utilization of an MRI versus no MRI.

TERTIARY/EXPLORATORY OBJECTIVE:

I. To compare treatment efficacy for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo treatment planning with a CT scan for HDR brachytherapy.

ARM B: Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.

After completion of study intervention, patients are followed up at 1, 3, 6, and 12 months.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University Hospital/Winship Cancer Institute
        • Kontakt:
        • Ledende efterforsker:
          • Kamran Salari, MD
      • Atlanta, Georgia, Forenede Stater, 30308
        • Rekruttering
        • Emory University Hospital Midtown
        • Kontakt:
        • Ledende efterforsker:
          • Kamran Salari, MD
      • Atlanta, Georgia, Forenede Stater, 30308

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  • Men ≥ 18 years old
  • Histopathologically confirmed prostate cancer
  • No evidence of regional or distant metastases
  • Plan to undergo curative-intent HDR brachytherapy with or without external beam radiation therapy

Exclusion Criteria:

  • Prior pelvic radiation therapy
  • No prior prostate MRI

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A (CT, SOC HDR brachytherapy)

Patients undergo treatment planning with a CT scan for HDR brachytherapy.

Ancillary studies

Eksperimentel: Arm B (CT, MRI, SOC HDR brachytherapy)

Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.

Ancillary studies

Undergo MRI scan

Andre navne:
  • MR
  • Magnetisk resonans
  • Magnetisk resonansbilledscanning
  • Medicinsk billeddannelse, magnetisk resonans / kernemagnetisk resonans
  • HR
  • MR billeddannelse
  • MR-scanning
  • NMR billeddannelse
  • NMRI
  • Kernemagnetisk resonansbilleddannelse
  • Magnetisk resonansbilleddannelse (MRI)
  • sMRI
  • Magnetisk resonansbilleddannelse (procedure)
  • MRI'er
  • Strukturel MR

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
Tidsramme: At 1 month following treatment

The primary analysis will be conducted using a mixed-effects model for repeated measures (MMRM) including fixed effects for treatment arm, categorical time, treatment-by-time interaction, baseline Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence score, age, comorbidity status, and the stratification factors of high-dose-rate treatment approach and rectal spacer use. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. The primary treatment comparison will be the adjusted between-group difference at the 1-month time point derived from the treatment-by-time interaction using least-squares means, with corresponding two-sided 95% confidence intervals and p-values evaluated at a significance level of 0.05.

At 1 month following treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
Tidsramme: At 3, 6 and 12 months following treatment

Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother.

At 3, 6 and 12 months following treatment
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Irritative/Obstructive, Bowel, and Sexual domain scores
Tidsramme: At 1, 3, 6 and 12 months following treatment

Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary irritative/obstructive, bowel, and sexual domain scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother.

At 1, 3, 6 and 12 months following treatment
Cumulative incidence of grade 2 or higher genitourinary or gastrointestinal adverse events
Tidsramme: Within 12 months following treatment

Will be analyzed using competing-risk methods to account for death as a competing event. Cumulative incidence functions will be estimated for each treatment arm and compared using Gray's test. Fine-Gray subdistribution hazard models, including stratification factors and relevant covariates, will be used to estimate adjusted hazard ratios with 95% confidence intervals. Adverse events will be coded using the Medical Dictionary for Regulatory Activities and graded according to Common Terminology Criteria for Adverse Events version 5.0. Safety analyses will summarize the frequency, severity, and relationship of adverse events to study treatment by System Organ Class and preferred term. Each adverse event will be counted once per participant at the maximum severity grade. Serious adverse events and events leading to treatment discontinuation will be summarized separately.

Within 12 months following treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Kamran Salari, MD, Emory University Hospital/Winship Cancer Institute

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. oktober 2026

Primær færdiggørelse (Anslået)

31. maj 2028

Studieafslutning (Anslået)

31. maj 2029

Datoer for studieregistrering

Først indsendt

1. oktober 2026

Først indsendt, der opfyldte QC-kriterier

1. oktober 2026

Først opslået (Faktiske)

6. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2026P000571
  • P30CA138292 (U.S. NIH-bevilling/kontrakt)
  • NCI-2026-06309 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • 2026P000571 (Anden identifikator: Emory University Hospital/Winship Cancer Institute)
  • RAD6975-26 (Anden identifikator: Emory University Hospital/Winship Cancer Institute)

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner